GlassScriptPhysician profile
Brendan B Pillemer
NPI 1184850992
$13,510.25
in general payments reported to CMS, 2019-2025
33 companies · $2,233 in 2025
The $2,233 reported for 2025 was more than what 78% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,702 · 2020: $702 · 2021: $774 · 2022: $1,945 · 2023: $3,128 · 2024: $3,027 · 2025: $2,233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,063 · Education: $325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,063.15 |
| Education | $324.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,928.35 | 2019-2025 | Tremfya |
| Abbvie INC. | $1,383.12 | 2019-2025 | |
| Lilly USA, LLC | $965.22 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $853.57 | 2019-2025 | |
| Galderma Laboratories, L.P. | $847.21 | 2019-2025 | Aklief, Nemluvio, Twyneo |
| Incyte Corporation | $700.73 | 2022-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $672.73 | 2023-2025 | Zoryve |
| Mayne Pharma Commercial LLC | $670.40 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $639.70 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $631.17 | 2019-2025 | Ilumya, Winlevi |
| Ucb, INC. | $570.89 | 2019-2025 | Bimzelx, Cimzia |
| Dermavant Sciences, INC. | $512.19 | 2022-2024 | Vtama |
| Genzyme Corporation | $408.76 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $386.37 | 2019-2024 | Duobrii, Siliq, Targretin |
| Leo Pharma INC. | $340.59 | 2019-2024 | Adbry |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $330.61 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $294.89 | 2019-2025 | Dupixent, Libtayo |
| Amgen INC. | $227.26 | 2021-2025 | Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $213.96 | 2022-2025 | Spevigo |
| Almirall LLC | $150.90 | 2019-2025 | Klisyri |
| Celgene Corporation | $133.35 | 2019 | |
| Journey Medical Corporation | $112.03 | 2019-2025 | |
| Organon LLC | $109.64 | 2025 | Vtama |
| Krystal Biotech INC | $92.22 | 2023 | Vyjuvek |
| Dermira, INC. | $71.59 | 2019-2021 | |
| Epi Health, LLC | $57.94 | 2020-2022 | |
| Vyne Pharmaceuticals INC. | $43.69 | 2021 | |
| Aclaris Therapeutics, INC. | $39.99 | 2019 | |
| Kyowa Kirin, INC. | $39.16 | 2022 | |
| Paratek Pharmaceuticals, INC. | $37.52 | 2022 | |
| Botanix Sb INC | $16.48 | 2025 | Sofdra |
| Prugen, INC. Pharmaceuticals | $14.19 | 2019 | |
| Merck Sharp & Dohme LLC | $13.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brendan Pillemer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.